Platform
HylX platform
HylMusa™ — Mucosal-Targeted HA Delivery for Autoimmune and Inflammatory Diseases
- HylMusa™ is an innovative hyaluronan-based platform optimized for localized mucosal delivery. By leveraging HA’s innate mucoadhesive properties and receptor-mediated uptake, HylMusa™ enables site-specific deposition and sustained exposure of anti-inflammatory or immunomodulatory payloads directly at mucosal surfaces.
- HylMusa™ platform is specifically designed to overcome the challenges of traditional therapies for mucosal disorders, where provides soft barrier protection, enhances local concentrations of payloads, improves mucosal healing, and reduces systemic burden tuning HA molecular properties to match tissue microenvironments.
- Preclinical validation with IBD98M, demonstrates HylMusa™ to deliver 5-aminosalicylic acid (5-ASA) in a targeted, colon-specific manner, and showed superior mucosal healing and anti-inflammatory efficacy compared to conventional 5-ASA formulations. Phase IIa clinical studies for ulcerative colitis demonstrated significant symptom relief with a reduced systemic drug burden.
- HylMusa™ offers pharmaceutical partners a differentiated solution for autoimmune and mucosal indications in gastrointestinal tract.
Mode of Action
-
Inflamed colon - LMW HA penetration-epithelial restitution of healthy cells
- HMW HA coating-protection
- Healthy colon restored
Inflamed colon
LMW HA penetration-epithelial restitution of healthy cells
HMW HA coating-protection
Healthy colon restored